Table 1.
Laboratory and clinical characteristics of r-GPA patients and HC
| r-GPA | HC | |
|---|---|---|
| Subjects, n (% male) | 63 (% 44) | 42 (% 40) |
| Age, mean (range) | 62.3 (26.8–85.2) | 57.2 (21.5–86.8) |
| PR3-ANCAa, n (% positive) | 39 (% 62) | |
| PR3-ANCA titer, median (range) | 1:40 (0–1:640) | |
| Creatinine umol/L, median (range) | 86 (52–224) | |
| CRP mg/L, median (range) | 2.7 (0.3–99) | |
| eGFR ml/min*1.73 m2, median (range) | 64 (21–109) | |
| CMV seropositive, n (% positive) (N.D.) | 33 (% 54) (2) | 21 (% 58) (6) |
| S. aureus, n (% positive) (N.D.) | 27 (% 44) (1) | |
| BVAS, mean | 0 | |
| Disease duration in years, median (range) | 9.6 (1.9–42.7) | |
| No. of total relapses, median (range) | 1 (0–7) | |
| Relapserb, n (%) | 43 (% 68) | |
| Disease type, n (% generalized) | 52 (% 83) | |
| Treatment at time of sampling, n (%) | ||
| Azathioprine | 3 (% 5) | |
| Azathioprine + prednisolone | 12 (% 19) | |
| Prednisolone | 6 (% 10) | |
| Mycophenolate mofetil + prednisolone | 7 (% 11) | |
| Methotrexate | 1 (% 2) | |
| No immunosupressive treatment | 34 (% 54) | |
| Co-trimoxazole, high dose/low dose/no dose | 17/15/31 | |
| No. of organs involved, median (range) | 3 (1–7) | |
| Clinical manifestations, n (%) | ||
| Renal | 35 (% 56) | |
| ENT | 45 (% 71) | |
| Joints | 36 (% 57) | |
| Pulmonary | 40 (% 63) | |
| Nervous system | 20 (% 32) | |
| Eyes | 24 (% 38) | |
| Cutaneous | 13 (% 21) | |
| Other | 7 (% 11) | |
Characteristics at sampling time point
BVAS Birmingham Vasculitis Activity Score, CMV cytomegalovirus, CRP C-reactive protein, eGFR estimated glomerular filtration rate, ENT ear, nose and throat, GPA granulomatosis with polyangiitis, HC healthy control, PR3-ANCA antineutrophil cytoplasmic antibodies targeting proteinase 3, r-GPA GPA patient in remission, S. aureus Staphylococcus aureus
aANCA-positive titer ≥1:40, ANCA-negative ≤1:20
bRelapser: GPA patient that had ≥1 relapse after diagnosis until time of sampling